Anzeige
Mehr »
Dienstag, 09.06.2026 - Börsentäglich über 12.000 News
Pentagon in Alarmbereitschaft? Dieser Rohstoff könnte jetzt Gold in den Schatten stellen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Business Wire
34 Leser
Artikel bewerten:
(0)

Texas Corneal Transplant Patient Files Lawsuit Against Advanced Medical Optics For ''Unbearable Pain'' and Permanent Vision Loss In Contact Lens Solution Recall Litigation

Signaling an expansion of the litigation against Santa Ana, California-based Advanced Medical Optics, Inc. ("AMO"), the national law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that Fort Worth, Texas resident Debbie Wooten filed today a personal injury lawsuit for damages suffered against AMO in federal court in Los Angeles.

Wooten, a 44-year-old operations manager at a financial services company, alleges she has suffered permanent vision loss due to Acanthamoeba keratitis, a extremely painful infection of the cornea, from use of AMO's Complete MoisturePlus Multi Purpose contact lens solution.

"The infestation in my left eye destroyed my cornea. I had to administer drops in my eye for a year," explained Wooten. "At first I had to administer the drops every hour around the clock. It took twenty minutes to administer the drops because I had to wait five minutes between each drop. The pain was unbearable. The microorganisms were chewing on my nerve endings."

Wooten was a regular purchaser of AMO contact lens solution, using the product as instructed. In late 2004, she began to suffer symptoms of light sensitivity, tearing, and redness. Wooten sought medical attention but her doctors were unable to accurately diagnose her condition. At the end of 2004, Wooten lost the vision in her left eye. In January 2005, Wooten was diagnosed with Acanthamoeba keratitis.

"Once the treatment ended, I then had to wait nine months for the corneal replacement surgery in case the infestation was dormant," Wooten stated. "I am extremely fortunate that I did not lose my eye but my vision is still impaired. I may need additional surgery. This was a terrible experience. I hope my lawsuit causes AMO to ensure its contact lens solution products are safe to use."

"AMO has not yet acknowledged its responsibilities to injured consumers," stated Wendy R. Fleishman, a partner at Lieff Cabraser. "AMO must compensate all users of its contact lens solution who developed serious eye infections, including reimbursing patients for the cost of their surgeries and other expenses, and agree to pay for necessary future medical care."

On May 25, 2007, the Food and Drug Administration alerted health care professionals and their patients who wear soft contact lenses about a voluntary recall of AMO's Complete MoisturePlus Multi Purpose. The recall was undertaken because of reports of a link between a rare, but serious eye infection, Acanthamoeba keratitis, caused by a parasite and use of AMO's contact lens solution.

AMO aggressively promoted Complete MoisturePlus Multi Purpose to healthcare professionals as well as to consumers with representations that it was a "highly effective cleaning agent" and that it "is effective against the introduction of common ocular microorganisms."

The Complaint charges that AMO's contact lens solution was not effective in disinfecting contacts lenses, and vastly inferior to other multipurpose solutions available on the market. The Complaint alleges that AMO's own data demonstrated the product's lack of effectiveness in preventing the growth of protozoa microorganisms, including "acanthameoba." The protozoa acanthameoba are directly associated with a disproportionate risk and increased incidence of Acanthamoeba keratitis in users of contact lens solution products.

Wooten's lawsuit brings claims of negligence, strict liability, breach of warranty, fraud, unjust enrichment, and violations of California statutory law. Wooten seeks compensatory and punitive damages against AMO for the injuries she has suffered.

About Lieff Cabraser Heimann & Bernstein, LLP

With three offices nationwide, Lieff Cabraser is one of the largest law firms in America dedicated solely to advancing the rights of plaintiffs. For the last four years, The National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the United States.

Lieff Cabraser has a superior reputation and a track record of successfully representing victims in all types of cases involving death or catastrophic injuries. Our staff of experienced attorneys and eleven in-house legal nurse consultants and medical analysts assures that each client receives high-level, individualized case review and representation.

Lieff Cabraser is representing contact lens users across America who developed serious eye injuries from AMO's products. Injured patients who wish to speak to Lieff Cabraser about their legal rights and remedies without any charge or obligation may contact attorney Kent L. Klaudt toll-free at 1-800-541-7358 or by email at kklaudt@lchb.com or Wendy Fleishman toll free at 888-321-1510 or by email at wfleishman@lchb.com.

To learn more about the AMO contact lens solution recall and litigation against the company, visit http://www.personalinjurylawyeramerica.com/medical/amo-contact-lens- solution-recall.htm (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Source/contact:

Wendy R. Fleishman
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP
780 Third Avenue, 48th Floor
New York, NY 10017
Telephone: (212) 355-9500
Email: wfleishman@lchb.com

Kent Klaudt
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP
275 Battery Street, 30th Floor
San Francisco, CA 94111
Telephone: (415) 956-1000
Email: kklaudt@lchb.com
© 2007 Business Wire
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.